1 – 10 of 18
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Targeting TUBG1 in RB1-negative tumors
(2025) In FASEB journal : official publication of the Federation of American Societies for Experimental Biology 39(5).
- Contribution to journal › Article
-
Mark
First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
- Contribution to journal › Article
- 2024
-
Mark
HLA investigation in ICI-induced T1D and isolated ACTH deficiency including meta-analysis
- Contribution to journal › Article
-
Mark
PROTAC-mediated conditional degradation of the WRN helicase as a potential strategy for selective killing of cancer cells with microsatellite instability
- Contribution to journal › Article
-
Mark
Long-Term Pattern of Psychotropic Medication Uses Among Swedish Parents of Children Diagnosed With Cancer
- Contribution to journal › Article
-
Mark
Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States : A comparative study of accelerated approvals
- Contribution to journal › Article
- 2022
-
Mark
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity
- Contribution to journal › Article
-
Mark
Sedation in specialized palliative care : A cross-sectional study
- Contribution to journal › Article
- 2019
-
Mark
ABC transporters as cancer drivers : Potential functions in cancer development
- Contribution to journal › Scientific review
- 2015
-
Mark
Targeted immunotherapies overtaking emerging oncology market value based growth
- Contribution to journal › Letter
